Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report issued on Monday. The brokerage set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Arcadia Biosciences in a report on Friday, April 5th.

Arcadia Biosciences Price Performance

Shares of RKDA stock opened at $2.09 on Monday. The stock’s fifty day simple moving average is $2.36 and its 200 day simple moving average is $2.73. The firm has a market cap of $2.84 million, a price-to-earnings ratio of -0.15 and a beta of 0.60. Arcadia Biosciences has a one year low of $1.85 and a one year high of $7.30.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Thursday, March 28th. The basic materials company reported ($2.48) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.20. Arcadia Biosciences had a negative return on equity of 81.56% and a negative net margin of 246.80%. The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.80 million. On average, research analysts anticipate that Arcadia Biosciences will post -5.01 earnings per share for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.